For invasive breast cancers that overexpress HER2 protein (reported range between 15–30%)3, trastuzumab offers a highly effective targeted therapy that can ameliorate the prognostic deficit inferred on patients with HER2 gene amplification. Here, ERBB2 is linked to invasive breast carcinoma.